Compass Therapeutics (CMPX) Price & Analysis

Compare

483 Followers

CMPX Stock Chart & Stats

$5.15

$0.48(33.57%)

At close: Jan 08 4:00 PM EST

$5.15

$0.48(33.57%)

Day’s Range― - ―

52-Week Range$1.33 - $6.88

Previous CloseN/A

Volume16.21M

Average Volume (3M)1.87M

Market Cap

$927.45M

Enterprise Value$691.36M

Total Cash (Recent Filing)$208.91M

Total Debt (Recent Filing)$9.83M

Price to Earnings (P/E)―

Beta2.21

Next Earnings

May 13, 2026

EPS Estimate

-0.1

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.09

Shares Outstanding180,087,920

10 Day Avg. Volume1,725,689

30 Day Avg. Volume1,870,488

Financial Highlights & Ratios

PEG Ratio-0.76

Price to Book (P/B)4.30

Price to Sales (P/S)0.00

P/FCF Ratio-17.22

Enterprise Value/Market Cap0.75

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-13.16

Forecast

1Y Price Target

$12.72

Price Target Upside146.99% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)-0.4

Revenue Forecast (FY)$1.42M

Bulls Say, Bears Say

Bulls Say

Market Expansion And AdoptionExpansion of tovecimig into first-line biliary tract cancer and other DLL4-positive tumors, together with investigator-led studies, could broaden the drug's market opportunity and encourage clinician adoption.

Pipeline DifferentiationEarly cohort responses for CTX-8371 indicate a differentiated bispecific mechanism that could materially increase asset value if expanded breast and lung cancer data confirm deep and durable responses.

Regulatory Approval ProspectsAnalyst expects final progression-free and overall survival results from the COMPANION-002 study to support a regulatory filing in biliary tract cancer if a meaningful benefit is confirmed.

Bears Say

Financing And Execution RiskOngoing clinical development paired with current cash burn may require the company to seek additional funding, raising the possibility of dilution or execution risk if financing terms are unfavorable.

Safety And Tolerability RiskCombining multiple agents introduces safety risks that could lead to tolerability issues or toxicities, potentially limiting trial success or clinical uptake of combination regimens.

Trial Design And Statistical InterpretationAllowed patient crossover in the pivotal trial may complicate overall survival interpretation, creating reliance on adjusted analyses that could be viewed as less definitive by regulators or investors.

Compass Therapeutics News

Compass Therapeutics reports Q4 EPS (9c), consensus (9c)

“2025 marked a year of significant progress for Compass, highlighted by our lead asset tovecimig successfully meeting the...

18d ago

CMPX

CMPX Upcoming Earnings Report: What to Expect?

Compass Therapeutics, Inc. (CMPX) is scheduled to report 4th quarter earnings on 02/27/2026. Regarding Q4 estimates, Wall Street...

26d ago

CMPX

Buy Rating on Tovecimig Driven by Early Efficacy Signals and Differentiated Risk–Benefit Profile in Biliary Tract Carcinoma

Analyst John Newman of Canaccord Genuity maintained a Buy rating on Compass Therapeutics, retaining the price target of...

27d ago

CMPX

Compass Therapeutics Moves CTX-10726 Into the Clinic: What Early Investors Should Know

Compass Therapeutics, Inc. ($CMPX) announced an update on their ongoing clinical study. The Phase 1 study “A Phase...

1M ago

CMPX

3 Strong Buy Stocks With 100%+ Upside, According to Top Analysts, 2/16/2026

Looking for top-rated stocks to buy now? Based on recent analyst updates, the three companies below have all...

1M ago

BTDR

CMPX

Craig-Hallum bullish on Compass Therapeutics, initiates with a Buy

As previously reported, Craig-Hallum initiated coverage of Compass Therapeutics (CMPX) with a Buy rating and $15 price target...

1M ago

CMPX

Compass Therapeutics initiated with a Buy at Craig-Hallum

Craig-Hallum initiated coverage of Compass Therapeutics (CMPX) with a Buy rating and $15 price target Published first on...

1M ago

CMPX

Compass Therapeutics price target raised to $13 from $10 at Canaccord

Canaccord raised the firm’s price target on Compass Therapeutics (CMPX) to $13 from $10 and keeps a Buy...

2M ago

CMPX

Compass Therapeutics: Strengthening Clinical Pipeline and 2026 Milestones Underscore Buy Rating and Upside Potential

Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on Compass Therapeutics. The associated price target...

2M ago

CMPX

Compass Therapeutics: Strong Cash Position and 2026 Clinical Catalysts Underpin Reiterated Buy Rating

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Compass Therapeutics, retaining the price target of...

3M ago

CMPX

Compass Therapeutics provides corporate update

Compass Therapeutics (CMPX) provided a general business update highlighting progress throughout its pipeline of clinical-stage drug candidates. The...

3M ago

CMPX

Compass Therapeutics details cash runway and pipeline progress

Compass Therapeutics ( ($CMPX) ) has issued an update. On January 6, 2026, Compass Therapeutics reported an estimated,...

3M ago

CMPX

Compass Therapeutics appoints Arjun Prasad as CCO, Cynthia Sirard as CMO

Compass Therapeutics (CMPX) announced the appointments of Arjun Prasad, MBA, MPH as Chief Commercial Officer and Cynthia Sirard,...

3M ago

CMPX

Compass Therapeutics initiated with an Outperform at William Blair

William Blair initiated coverage of Compass Therapeutics (CMPX) with an Outperform rating and no price target The firm...

3M ago

CMPX

CMPX FAQ

What was Compass Therapeutics’s price range in the past 12 months?

Compass Therapeutics lowest stock price was $1.33 and its highest was $6.88 in the past 12 months.

What is Compass Therapeutics’s market cap?

Compass Therapeutics’s market cap is $927.45M.

When is Compass Therapeutics’s upcoming earnings report date?

Compass Therapeutics’s upcoming earnings report date is May 13, 2026 which is in 51 days.

How were Compass Therapeutics’s earnings last quarter?

Compass Therapeutics released its earnings results on Mar 05, 2026. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.094 by $0.004.

Is Compass Therapeutics overvalued?

According to Wall Street analysts Compass Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Compass Therapeutics pay dividends?

Compass Therapeutics does not currently pay dividends.

What is Compass Therapeutics’s EPS estimate?

Compass Therapeutics’s EPS estimate is -0.1.

How many shares outstanding does Compass Therapeutics have?

Compass Therapeutics has 180,087,920 shares outstanding.

What happened to Compass Therapeutics’s price movement after its last earnings report?

Compass Therapeutics reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.094. Following the earnings report the stock price went down -2.812%.

Which hedge fund is a major shareholder of Compass Therapeutics?

Currently, no hedge funds are holding shares in CMPX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Compass Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-43.61%

Trailing 12-Months

Asset Growth

58.22%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Compass Therapeutics

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Compass Therapeutics (CMPX) Earnings & Revenues

Historic Earnings Reports

CMPX Stock 12 Month Forecast

Average Price Target

$12.72

▲(146.99% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","25":"$25","6.25":"$6.25","12.5":"$12.5","18.75":"$18.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.72,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.72</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.78,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.78</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,6.25,12.5,18.75,25],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.68,7.089230769230769,8.498461538461537,9.907692307692308,11.316923076923077,12.726153846153846,14.135384615384616,15.544615384615385,16.953846153846154,18.363076923076925,19.77230769230769,21.181538461538462,22.590769230769233,{"y":24,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.68,6.2215384615384615,6.763076923076923,7.304615384615385,7.846153846153847,8.387692307692308,8.92923076923077,9.470769230769232,10.012307692307694,10.553846153846155,11.095384615384617,11.636923076923079,12.178461538461539,{"y":12.72,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.68,5.687692307692307,5.695384615384615,5.703076923076923,5.71076923076923,5.718461538461538,5.726153846153846,5.733846153846154,5.741538461538462,5.74923076923077,5.756923076923077,5.764615384615385,5.772307692307693,{"y":5.78,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.22,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.82,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.15,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.58,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.74,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.46,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.37,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.52,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.68,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >